Ronald C. Renaud, Jr.
Angela Rasmussen, PhD
Associate Research Scientist
Julianna LeMieux, PhD
Senior Science Writer
Senior Business Writer
Broadcast Date: September 16, 2020
Time: 2:00 pm ET
The COVID-19 pandemic has now claimed more than 500,000 lives, including 180,000 in the United States. The biotech and pharma industries are working furiously to develop therapeutics and a vaccine. Several vaccine candidates are now in the clinic, with promising early-stage results reported by Pfizer, AstraZeneca, and others.
Join us for Episode 4 of GEN Live, in which we discuss the state of vaccine development for COVID-19. We evaluate the front-runners, explore the potential of RNA vaccines, ponder the challenges of manufacturing, and tackle questions about herd immunity.
• Julianna LeMieux – GEN Senior Science Writer
• Alex Philippidis – GEN Senior Business Writer
• Ronald Renaud select CEO Translate Bio)
• Angela Rasmussen, PhD select Center for Infection and Immunity, Columbia University Mailman School of Public Health)
Moderated by: Kevin Davies select GEN/The CRISPR Journal)
Produced with support from: